Regeneron Pharmaceuticals, Inc. v Merus N.V

Link copied
Case Copied 67 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Regeneron Pharmaceuticals, Inc. v Merus N.V. [2017] APO 19

Patent:2009263082

Title:Antibody producing non-human mammals

Patent Applicant:                   Merus N.V.

Opponent:  Regeneron Pharmaceuticals, Inc.

Delegate:  Dr B. Akhurst

Decision Date:  5 May 2017

Hearing Date:  13 & 14 September 2016 in Melbourne, with additional evidence and submissions filed by the parties on 5 and 19 October 2016

Catchwords:  PATENTS – section 59 opposition to grant of a patent – grounds of novelty, inventive step, utility, fair basis, clarity, and definition of the invention – novelty – a prior disclosure of a transgenic mouse model provides a clear description of a transgenic mouse that in fact falls within the scope of opposed claims – other grounds unsuccessful – costs awarded – opportunity to amend.  

Representation:  Counsel for the applicant:  Christian Dimitriadis.

Patent attorneys for the applicant:  James Cherry and Adam Denley of Freehills Patent Attorneys.

Counsel for the opponent:  Ben Fitzpatrick.

Patent attorneys for the opponent:  Mark Wickham and David Longmuir of Phillips Ormonde Fitzpatrick.

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2009263082

Title:Antibody producing non-human mammals

Applicant:  Merus N.V.

Date of Decision:                   5 May 2017

DECISION

The opposition succeeds.  Claims 1-3, 5-7, 9-13 and 24-26 lack novelty.

Merus N.V has 2 months from the date of this decision to propose amendments to the claims.

Costs are awarded according to Schedule 8 against Merus N.V.

REASONS FOR DECISION

Background

  1. Merus N. V. (the applicant) filed patent application 2009263082 on 29 June 2009, via the PCT, claiming priority from application PCT/NL2008/050430 filed on 27 June 2008.  Following examination, application 2009263082 was advertised as accepted on 20 March 2014. 

  2. Regeneron Pharmaceuticals, Inc. (the opponent) filed a notice of opposition on 20 June 2014 and a statement of grounds and particulars (SGP) on 22 September 2014.  Evidence in support, answer and reply was completed on 22 December 2014, 2 June 2015 and 19 October 2015, respectively.  The matter was heard on 13 and 14 September 2016 at IP Australia’s Melbourne Patent Examination Centre. 

  3. At the hearing, I gave the parties a period of time in which to file evidence and responding evidence on a particular point in relation to a document I had admitted into the hearing under reg 5.23.  This evidence was filed on 5 October 2016 and 19 October 2016, respectively.

    The Evidence

  4. Evidence in support of the opposition consisted of declarations by:

    ·David Tarlinton dated 21 December 2014 (Tarlinton#1) with Exhibits DT-1 and DT-2;

    ·Anthony L. De Franco dated 21 December 2014 (DeFranco#1) with Exhibits ALD-1 to ALD-4; and

    ·Andrew Murphy dated 21 December 2014 (Murphy#1) and Annexure 1.

  5. Evidence in answer consisted of declarations by:

    ·Robert Brink dated 30 April 2015 (Brink#1) with Exhibits RB-1 and RB-2;

    ·Robert Brink dated 2 June 2015 (Brink#2) with Exhibits RB-3 to RB-6;

    ·Peter Hudson dated 1 May 2015 (Hudson#1) with Exhibits PH-1 to PH-3;

    ·Peter Hudson dated 2 June 2015 (Hudson#2

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Regeneron Pharmaceuticals, Inc. v Merus N.V and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2017] APO 19
Decision Date

CaseChat Overview and Summary

Regeneron Pharmaceuticals, Inc. opposed the grant of a patent to Merus N.V. for a transgenic murine mammal capable of producing human antibodies. The dispute centred on the novelty, utility, inventive step, and clarity of the patent claims. The Australian Patent Office found that the claims lacked novelty because they were anticipated by a prior disclosure of a transgenic mouse model. The court determined that the transgenic mouse disclosed in the prior art provided a clear description of a transgenic mouse that fell within the scope of the opposed claims. The court also found that the claims lacked fair basis and clarity. The opposition was successful, and Merus N.V. was given two months to propose suitable amendments to the claims. Costs were awarded against Merus N.V.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.